Full text

Turn on search term navigation

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):571‐592. doi:10.1159/000506103

Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110‐120. doi:10.1016/S0140-6736(20)30609-7

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: [eLocator: n71]. doi:10.1136/bmj.n71

Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: [eLocator: l4898]. doi:10.1136/bmj.l4898

Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445‐1455. doi:10.1056/NEJMoa2118828

Speeckaert R, van Geel N. Vitiligo: an update on pathophysiology and treatment options. Am J Clin Dermatol. 2017;18(6):733‐744. doi:10.1007/s40257-017-0298-5

Word count: 143

Show less

© 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Details

Title
Efficacy and safety of topical ruxolitinib cream for the treatment of vitiligo: A systematic review and meta‐analysis of randomized controlled trials
Author
Ehsan, Muhammad 1 ; Rehman, Aqeeb Ur 1 ; Ayyan, Muhammad 1 ; Cheema, Huzaifa Ahmad 1   VIAFID ORCID Logo  ; Ahmad, Talha Zartash 1 ; Mustafa, Biah 1 ; Shahid, Abia 1 ; Khedro, Tarek 2 ; Ismail, Heba 3 ; Nashwan, Abdulqadir J. 4   VIAFID ORCID Logo 

1  Department of Medicine, King Edward Medical University, Lahore, Pakistan 
2  Department of Internal Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland 
3  Department of Internal Medicine, Limerick University Hospital, Limerick, Ireland 
4  Hamad Medical Corporation, Doha, Qatar 
Pages
350-353
Section
LETTERS TO THE EDITOR
Publication year
2024
Publication date
Jan 1, 2024
Publisher
John Wiley & Sons, Inc.
ISSN
14732130
e-ISSN
14732165
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1111/jocd.15921
ProQuest document ID
3090613657
Copyright
© 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.